Valbiotis: encouraging results in hypertension
The results demonstrated a protective effect of TOTUM 854 on vascular wall cells and a reduction in angiotensin I-converting enzyme (ACE1) activity in humans.
These solid data confirm TOTUM 854's potential for reducing blood pressure in its early stages, which affect 123 million people in the United States and Europe. They are very promising for the final stage of TOTUM 854's clinical development", the company emphasizes.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction